Tempest Therapeutics, Inc. - Common Stock (TPST)

Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.

Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 study showing improved survival in patients with unresectable hepatocellular carcinoma.

Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin in Q1 2025.

TPST stock results show that Tempest Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows a six-month survival improvement in hepatocellular carcinoma patients using TPST-1120 combined with atezolizumab and bevacizumab.

NLS Pharmaceutics stock is down on Thursday as shares of NLSP come off of a recent rally that was fueled by heavy trading on Tuesday.

Avrobio stock is in the news Thursday as the company prepares for a merger and reverse stock split of AVRO after markets close today.

Tempest Therapeutics stock is up on Thursday with heavy trading of TPST shares ahead of a presentation taking place this morning.

Pre-market stock movers are a hot topic on Thursday and we have all the hottest news behind these movements this morning!

TPST stock results show that Tempest Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition.

TPST stock results show that Tempest Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.